Improvement of Cyclophosphamide-Induced Immunosuppression by Miaoyao Fanggan Sachet Extract

Chemotherapy drugs, such as cyclophosphamide, often produce side effects of immunosuppression in the treatment of tumors. This study investigated whether the Miaoyao Fanggan sachet extracts—diammonium glycyrrhizinate and magnesium isoglycyrrhizinate—can regulate respiratory immunity in mice. A cyclophosphamide-induced immunosuppressive mice model was treated with diammonium glycyrrhizinate and magnesium isoglycyrrhizinate. Interferon (IFN)-α, interferon-β, interleukin (IL)-6, and interleukin-18 levels in the bronchoalveolar lavage fluid and lung tissue were detected using enzyme-linked immunosorbent assay and quantitative reverse transcription-polymerase chain reaction, respectively. The p-(phospho) transforming growth factor beta-activated kinase 1 (TAK1)/TAK1 and p-IkappaB (IκB)/IκB in the lung tissue and bronchial mucosa were detected by Western blot. Compared with the control group, the IFN-α and IL-6 levels decreased, while IFN-βand IL-18 levels increased in the mice model. However, these changes were reversed with the treatment with diammonium glycyrrhizinate and magnesium isoglycyrrhizinate; p-TAK1/TAK1 and p-IκB/IκB in the model group decreased significantly and increased with the increasing treatment dose of diammonium glycyrrhizinate and magnesium isoglycyrrhizinate. Diammonium glycyrrhizinate and magnesium isoglycyrrhizinate had a certain effect on cyclophosphamide-induced immunosuppression in mice, likely mediated through the phosphorylation of TAK1 and IκB, activating nuclear factor kappa-B and subsequently stimulating the Janus kinase/signal transducer and activator of transcription/mitogen-activated protein kinase pathway.